Dr. Stephens is an expert in next-generation sequencing and cancer genome analysis who brings a breadth of experience in life sciences and the clinical diagnostics and laboratory industries. Dr. Stephens was Chief Scientific Officer at Foundation Medicine Inc (FMI) for nearly 8 years where he oversaw the development and commercialization of FMI's comprehensive cancer genomics diagnostic tests.

Dr. Naber was Chief of Pathology from 2002-2015 and serves as an Associate Chair in the Department of Pathology at Tufts University School of Medicine. Dr. Naber also previously directed Tufts's clinical laboratory and has been the recipient of National Institutes of Health and Department of Defense grants and awards for studies in studies of breast neoplasia, models of tumor development, and regulation of gene expression in human breast cancer.

Dr. Berger was the Chief Medical Officer for Exact Sciences Corporation, developer of the Cologuard DNA test for colorectal cancer screening. He is boarded in Anatomic, Clinical & Cytologic pathology. Most of his clinical career was spent at the Dept of Pathology and Lab Medicine of Harvard Pilgrim Healthcare [Chairman (1988-1999), Assoc Director (1982-1988)]. He has served on the Medicare Evidence Development and Coverage Advisory Comm. (2015).

Dr. Haydon is the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. He is an internationally recognized leader in the study of neuron-glial interactions in disease and a repeat entrepreneur who has co-founded multiple biotech companies.

Mr. Liem was at Thomas H. Lee Partners for seven years where he managed financial reporting, portfolio monitoring, and operations initiatives and was an integral part of the firm’s fundraising efforts. He has over 20 years of experience running finance and business operations at companies such as Nuance Communications, State Street Corporation, Fidelity Investments, The MathWorks Inc, Percussion Software, The World Bank & The Hackett Group.